Evidence analysisOctober 16, 2026Health & Science
Human medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 70, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
Remicade (active substance infliximab) is a monoclonal antibody medicine authorised in the European Union since 1999. It is used primarily as an anti-inflammatory treatment in several autoimmune diseases where inflammation is pathological, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.
Infliximab works by targeting and neutralising tumour necrosis factor-alpha (TNF-alpha), a cytokine with a central role in driving inflammation in these diseases. The medicine is administered intravenously, under specialist medical supervision, with dosing and frequency depending on the condition treated and patient response.
Clinical trials and studies conducted in adult patients with rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis have shown symptom improvement, decreased inflammation, and in some cases, improved joint function and fistula healing. In children and adolescents aged 6 to 17 with severe Crohn’s disease or ulcerative colitis unresponsive to other treatments, adding Remicade has demonstrated symptom reductions as well.
Common side effects include viral infections, headache, respiratory infections, sinusitis, nausea, abdominal pain, and infusion reactions. There are precautions against use in patients with active severe infections, hypersensitivity to infliximab or mouse proteins, and heart failure. Monitoring during and after infusion is standard practice to mitigate risks.
What the source claims
The European Medicines Agency (EMA) states that Remicade’s benefits outweigh its risks in properly selected patients and under specialist supervision. It authorises Remicade’s use across the EU with specific dosing protocols and safety measures including the distribution of a special reminder card for patients detailing safety information and test records.
The EMA notes evidence from multiple studies encompassing over a thousand patients per disease indication, supporting effectiveness in symptom reduction and disease control. Combination therapy with methotrexate in rheumatoid arthritis and azathioprine in Crohn’s disease may enhance efficacy compared to monotherapy.
Safety monitoring is ongoing, with side effect reports carefully evaluated to protect patients. Recommendations and contraindications are included in the summary of product characteristics and patient leaflets. Specific warnings highlight the risk of infections and hypersensitivity reactions.
What may be missing from the usual framing
While the EMA’s summary focuses on established benefits and safety under specialist care, it provides less detail on long-term effects beyond two years, varying efficacy across demographic groups, and the impact on quality of life metrics outside symptom assessment. There is also limited discussion of cost-effectiveness, patient access disparities, or comparative effectiveness against newer biologics and small molecule drugs in the same indications.
The summary does not address patient-reported outcomes or real-world adherence challenges with an intravenous infusion regime that requires medical facility visits. It also omits discussion on potential development of anti-drug antibodies over time, which may reduce effectiveness or increase adverse reactions.
Competing evidence or uncertainty
Evidence cited by EMA stems mainly from manufacturer-sponsored clinical trials and selected academic studies, which generally show statistically significant improvements. However, some independent studies suggest variability in response rates and occasional serious adverse events, including rare infections and malignancies, which remain areas of active pharmacovigilance.
There is limited high-quality long-term data on safety in pediatric populations, where use is less common but increasing. Criteria for switching between biologic agents or cessation of therapy in non-responders are still evolving. Treatment necessity and optimal timing of infusions vary between patients, contributing to uncertainty in maximal benefit prediction.
Why it matters
Remicade has been a foundational therapy in autoimmune inflammatory diseases for over two decades, offering patients refractory to conventional treatments a chance to control symptoms and improve function. Understanding its benefits and risks shapes clinical decisions in managing diseases that can cause disability and significantly impair quality of life.
Given the high cost and complexity of biologic therapies, clear evidence on efficacy, safety, monitoring, and long-term outcomes informs health policy, reimbursement decisions, and patient choice. Awareness of the limits of available data urges cautious optimism and continued research in this evolving field.
What to verify next
Readers are advised to consult the original EMA European Public Assessment Report on Remicade for comprehensive details on indications, clinical trial data, contraindications, dosing schedules, and safety information. Verification with up-to-date independent reviews and real-world studies would also help contextualise efficacy and safety profiles.
Future areas for investigation include longer-term safety data, comparative effectiveness against newer therapies, patient quality of life assessments, immunogenicity, and cost-effectiveness analyses across healthcare systems.
Source & verification
Primary source: What's new · October 16, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…